{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:58:31Z","timestamp":1782968311198,"version":"3.54.5"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>This study aimed to evaluate the clinical effectiveness of bilastine in type IIb autoimmune CSU (type IIb aiCSU) patients over an 8-week period, as well as to identify factors predicting treatment response.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>34 type IIb aiCSU patients with positive basophil histamine release assays (BHRA) and positive Autologous Serum Skin Test (ASST) tests, from the Vietnam National Dermatology and Venereology Hospital, were included. Patients began treatment with the standard dose of bilastine, with the dose increased every two weeks for those who did not achieve adequate response. The Urticaria Control Test (UCT), Weekly Urticaria Activity Score (UAS7), and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) were used.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Significant improvements in all measures were observed, with 82.4% of patients achieving complete response by week 8. Of these, 47.1% responded to the standard dose, while 14.7% did not respond even at the maximum (x4) dose. UAS7 average scores decreased from a baseline mean of 28.9 to 2.9, indicating substantial reduction in disease activity. UCT scores improved from 47.1% of patients having poor disease control (UCT\u2009&lt;\u200912) after week 2 to 85.3% achieving good control (UCT\u2009\u2265\u200912) by week 8. QoL also significantly improved, with CU-Q2oL scores dropping from 44.9 at baseline to 25.3 at week 8. Basopenia, high baseline UAS7 score and a history of autoimmune disease were associated with poorer treatment responses, while normal\/high IgE levels were linked to better outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The findings suggest that bilastine is highly effective in controlling aiCSU symptoms and improving QoL.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0326445","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:36:27Z","timestamp":1756143387000},"page":"e0326445","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria"],"prefix":"10.1371","volume":"20","author":[{"given":"My Tra Thi","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My Huyen","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Nguyet","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Stahl","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0474-8128","authenticated-orcid":true,"given":"Doanh Huu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"pone.0326445.ref001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA\u00b2LEN task force report","volume":"66","author":"M Maurer","year":"2011","journal-title":"Allergy"},{"issue":"10","key":"pone.0326445.ref002","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ddg.12194","article-title":"Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria","volume":"11","author":"M Maurer","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"pone.0326445.ref003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"BF O\u2019Donnell","year":"1997","journal-title":"Br J Dermatol"},{"issue":"12","key":"pone.0326445.ref004","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU","volume":"72","author":"M Maurer","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"pone.0326445.ref005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/1744666X.2014.892416","article-title":"Update and insights into treatment options for chronic spontaneous urticaria","volume":"10","author":"N Marrouche","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"pone.0326445.ref006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2040622315603951","article-title":"Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy","volume":"6","author":"C Vestergaard","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"pone.0326445.ref007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.35120\/medisij010355t","article-title":"Association of autoimmune status with asst, autoimmune and atopic diseases in csu patients","volume":"1","author":"V Trajkova","year":"2022","journal-title":"IJMSR"},{"issue":"3","key":"pone.0326445.ref008","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijd.ijd_1199_23","article-title":"A prospective randomized non-blinded study of safety and efficacy of bilastine up-dosing (40\u2009mg) versus combination of bilastine 20\u2009mg with levocetirizine 5\u2009mg in the treatment of chronic spontaneous urticaria","volume":"69","author":"B Sneha","year":"2024","journal-title":"Indian J Dermatol"},{"issue":"2","key":"pone.0326445.ref009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijd.ijd_722_23","article-title":"Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study","volume":"69","author":"A De","year":"2024","journal-title":"Indian J Dermatol"},{"key":"pone.0326445.ref010","article-title":"Levocetirizine versus Bilastine as Monotherapy in the Management of Chronic Spontaneous Urticaria: A Randomised Controlled Trial","author":"R Rajendran","year":"2024","journal-title":"JCDR"},{"issue":"3","key":"pone.0326445.ref011","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"T Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"pone.0326445.ref012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/all.12056","article-title":"EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria","volume":"68","author":"GN Konstantinou","year":"2013","journal-title":"Allergy"},{"issue":"12","key":"pone.0326445.ref013","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/cea.14402","article-title":"Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria","volume":"53","author":"K Baumann","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"pone.0326445.ref014","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"K Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"pone.0326445.ref015","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1398-9995.2005.00833.x","article-title":"A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL)","volume":"60","author":"I Baiardini","year":"2005","journal-title":"Allergy"},{"issue":"1","key":"pone.0326445.ref016","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14557","article-title":"Effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine: Real world experience in India","volume":"34","author":"B Shah","year":"2021","journal-title":"Dermatol Ther"},{"issue":"11","key":"pone.0326445.ref017","article-title":"H1-antihistamines for chronic spontaneous urticaria","volume":"2014","author":"M Sharma","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pone.0326445.ref018","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"S Guill\u00e9n-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0326445.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment","volume":"8","author":"P Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"pone.0326445.ref020","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"JS Fok","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"pone.0326445.ref021","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u201cidiopathic\u201d urticaria","volume":"143","author":"CE Grattan","year":"2000","journal-title":"Br J Dermatol"},{"issue":"11","key":"pone.0326445.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2023.09.055","article-title":"47 Bilastine in refractory chronic spontaneous urticaria: disease control and cytokine modulation in an open-label prospective study","volume":"143","author":"D Chakraborty","year":"2023","journal-title":"J Investigative Dermatol"},{"issue":"6","key":"pone.0326445.ref023","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13946","article-title":"Effectiveness, safety, and tolerability of bilastine 20\u2009mg vs levocetirizine 5\u2009mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial","volume":"33","author":"I Podder","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4","key":"pone.0326445.ref024","doi-asserted-by":"crossref","first-page":"328","DOI":"10.18231\/j.ijced.2020.066","article-title":"Real world Indian experience of switchover to Bilastine in CSU patient refractory to other antihistamines","volume":"6","author":"D Dhoot","year":"2020","journal-title":"IJCED"},{"issue":"1","key":"pone.0326445.ref025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/cdr.cdr_25_21","article-title":"Comparative Clinical Assessment of Updosing of Bilastine and Combination of Levocetirizine and Hydroxyzine in Chronic Spontaneous Urticaria","volume":"6","author":"B Shah","year":"2022","journal-title":"Clinical Dermatol Review"},{"key":"pone.0326445.ref026","first-page":"261","article-title":"Bilastine in higher doses in chronic spontaneous urticaria","volume":"5","author":"K Godse","year":"2019","journal-title":"J Clin Exp Dermatol"},{"key":"pone.0326445.ref027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.25259\/IJSA_3_2021","article-title":"The effectiveness of bilastine and fexofenadine updosing in the management of chronic spontaneous urticaria","volume":"1","author":"B Shah","year":"2022","journal-title":"IJSA"},{"issue":"2","key":"pone.0326445.ref028","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000527181","article-title":"Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis","volume":"184","author":"X Xue","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"pone.0326445.ref029","doi-asserted-by":"crossref","first-page":"1014924","DOI":"10.3389\/fimmu.2022.1014924","article-title":"Decreased peripheral basophil counts in urticaria and mouse model of oxazolone-induced hypersensitivity, the latter suggesting basopenia reflecting migration to skin","volume":"13","author":"I Kishimoto","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0326445.ref030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"P Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"pone.0326445.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.09.002","article-title":"Autoimmune Diseases and Low Baseline IgE in Chronic Spontaneous Urticaria: A Clinical and Therapeutic Prospective Analysis in Real-Life Clinical Practice","volume":"11","author":"D Pesqu\u00e9","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"pone.0326445.ref032","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.jaip.2023.06.026","article-title":"The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria","volume":"11","author":"M Maurer","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"pone.0326445.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE","volume":"9","author":"P Kolkhir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"pone.0326445.ref034","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"P Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"pone.0326445.ref035","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1159\/000532021","article-title":"Anti-TPO IgG\/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria","volume":"184","author":"R Br\u00e1s","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"pone.0326445.ref036","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/cea.12465","article-title":"Management of urticaria: not too complicated, not too simple","volume":"45","author":"M Ferrer","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"pone.0326445.ref037","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2045-7022-2-19","article-title":"A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria","volume":"2","author":"K Iqbal","year":"2012","journal-title":"Clin Transl Allergy"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:36:33Z","timestamp":1756143393000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326445"}},"subtitle":[],"editor":[{"given":"Benjamin","family":"Benzon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326445","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}